비교리스트

 카트 문의
시장보고서
상품코드
1346913

인터류킨-6(IL-6) 억제제 시장 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 질병 유형별, 유통 채널별, 지역별, 부문별 예측(2023-2032년)

Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023-2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 연구에 따르면, 인터류킨-6(IL-6) 억제제 세계 시장 규모는 2032년까지 863억 1,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

인터류킨-6(IL-6) 억제제의 인기가 높아짐에 따라 많은 기업과 조직이 연구개발에 투자하고 있습니다. 예를 들어, 2022년 12월 미국 식품의약국(FDA)은 정맥주사(IV) 토실리주맙(Actemra)을 특례 조치로 입원 환자에서 COVID-19 치료제로 승인했습니다. 토실리주맙은 FDA로부터 팬데믹 바이러스 치료제로 승인받은 최초의 단일클론항체로서, 로슈의 승인에 따른 것입니다. 이와 함께 2021년 9월, 헤테로는 인도 의약품감독청(DCGI)으로부터 입원 환자를 위한 COVID-19 치료제인 토실리주맙의 바이오시밀러 버전에 대한 판매 승인을 받았습니다. 여러 단체와 업계 진입 기업의 기여는 세계 시장 성장을 크게 촉진하고 있습니다.

자가면역질환 및 염증성 질환의 유병률 증가로 인해 IL-6는 류마티스 관절염, 청소년 특발성 관절염, 캐슬만병, 사이토카인 방출 증후군(CRS) 등 다양한 자가면역질환 및 염증성 질환의 발병에 중요한 역할을 하고 있어 세계 시장 개척을 가속화할 것으로 예상됩니다. 있습니다. 이러한 질환의 유병률이 전 세계적으로 증가함에 따라 IL-6 억제제와 같은 효과적인 치료제에 대한 수요가 증가하고 있습니다.

만성 염증성 질환의 유병률 증가는 시장의 세계 성장을 촉진하는 주요 요인 중 하나입니다. 류마티스 관절염, 청소년 특발성 관절염, 캐슬만병과 같은 만성 염증성 질환이 전 세계적으로 증가하고 있습니다. 예를 들어, 북미와 유럽에서는 어린이 1만 명 중 4-16명이 청소년 특발성 관절염을 앓고 있는 것으로 추정되며, IL-6 억제제는 이러한 질환의 증상과 진행을 조절하는 데 효과적인 것으로 나타나 IL-6 억제제 수요를 견인하고 있습니다. 이에 따라 세계 시장 개척이 활발히 진행되고 있습니다.

인터류킨-6(IL-6) 억제제 시장 보고서 및 하이라이트

토실리주맙(Tocilizumab)은 가장 먼저 승인되어 시장에 진입한 IL-6 억제제 중 하나이기 때문에 2022년에는 가장 큰 시장 점유율을 기록할 것으로 예상됩니다.

류마티스 관절염은 상대적으로 높은 유병률로 인해 세계 시장에서 가장 큰 매출을 올릴 것으로 예상됩니다.

전문 소매점은 IL-6 억제제의 중요한 유통 채널이기 때문에 2022년 세계 매출에서 가장 큰 점유율을 차지할 것으로 예상됩니다.

북미 지역은 기업 및 단체의 임상시험 증가와 업계 R&D의 급증으로 인해 2022년 기준 가장 큰 점유율을 차지할 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 인터류킨 6(IL-6) 억제제 시장에 관한 인사이트

  • 인터류킨 6(IL-6) 억제제 시장 - 유통 채널 현황
  • 인터류킨-6(IL-6) 억제제 시장 역학
    • 성장 촉진요인과 기회
      • 류마티스 관절염(RA) 유병률 증가
      • 인기가 높은 인터류킨 6억제제
    • 성장 억제요인과 과제
      • 개발비가 높은
  • PESTEL 분석
  • 인터류킨 6(IL-6) 억제제 시장 유통 채널 동향
  • 밸류체인 분석
  • COVID-19 감염증의 영향 분석

제5장 질환 종류별 세계 인터류킨 6(IL-6) 억제제 시장

  • 주요 조사 결과
  • 서론
  • 류마티스 관절염
  • 캐슬만병
  • 암(신장암, 전립선암)
  • 동맥염

제6장 세계의 인터류킨 6(IL-6) 억제제 시장, 약제 종류별

  • 주요 조사 결과
  • 서론
  • 토실리주맙
  • 시르트키시마브
  • 시르반트

제7장 세계의 인터류킨 6(IL-6) 억제제 시장, 유통 채널별

  • 주요 조사 결과
  • 서론
  • 소매 약국
  • 병원 약국
  • 전문 약국
  • 온라인 약국
  • 기타 판매 채널

제8장 세계의 인터류킨 6(IL-6) 억제제 시장, 지역별

  • 주요 조사 결과
  • 서론
    • 인터류킨 6(IL-6) 억제제 시장 평가, 지역, 2019-2032
  • 인터류킨 6(IL-6) 억제제 시장 - 북미
    • 북미 : 인터류킨 6(IL-6) 억제제 시장, 질환 유형별, 2019-2032년
    • 북미 : 인터류킨 6(IL-6) 억제제 시장, 유통 채널별, 2019-2032
    • 북미 : 인터류킨-6(IL-6) 억제제 시장, 약제 유형별, 2019-2032
    • 인터류킨 6(IL-6) 억제제 시장 - 미국
    • 인터류킨 6(IL-6) 억제제 시장 - 캐나다
  • 인터류킨 6(IL-6) 억제제 시장 - 유럽
    • 유럽 : 인터류킨 6(IL-6) 억제제 시장, 질환 유형별, 2019-2032년
    • 유럽 : 인터류킨 6(IL-6) 억제제 시장, 유통 채널별, 2019-2032
    • 유럽 : 인터류킨 6(IL-6) 억제제 시장, 약제 유형별, 2019-2032년
    • 인터류킨 6(IL-6) 억제제 시장 - 영국
    • 인터류킨 6(IL-6) 억제제 시장 - 프랑스
    • 인터류킨 6(IL-6) 억제제 시장 - 독일
    • 인터류킨 6(IL-6) 억제제 시장 - 이탈리아
    • 인터류킨 6(IL-6) 억제제 시장 - 스페인
    • 인터류킨 6(IL-6) 억제제 시장 - 네델란드
    • 인터류킨 6(IL-6) 억제제 시장 - 러시아
  • 인터류킨 6(IL-6) 억제제 시장 - 아시아태평양
    • 아시아태평양 : 인터류킨 6(IL-6) 억제제 시장, 질환 유형별, 2019-2032년
    • 아시아태평양 : 인터류킨 6(IL-6) 억제제 시장, 유통 채널별, 2019-2032년
    • 아시아태평양 : 인터류킨 6(IL-6) 억제제 시장, 약제 유형별, 2019-2032년
    • 인터류킨 6(IL-6) 억제제 시장 - 중국
    • 인터류킨 6(IL-6) 억제제 시장 - 인도
    • 인터류킨 6(IL-6) 억제제 시장 - 말레이시아
    • 인터류킨 6(IL-6) 억제제 시장 - 일본
    • 인터류킨 6(IL-6) 억제제 시장 - 인도네시아
    • 인터류킨 6(IL-6) 억제제 시장 - 한국
  • 인터류킨 6(IL-6) 억제제 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 인터류킨 6(IL-6) 억제제 시장, 질환 유형별, 2019-2032년
    • 중동 및 아프리카 : 인터류킨 6(IL-6) 억제제 시장, 유통 채널별, 2019-2032년
    • 중동 및 아프리카 : 인터류킨 6(IL-6) 억제제 시장, 약제 유형별, 2019-2032년
    • 인터류킨 6(IL-6) 억제제 시장 - 사우디아라비아
    • 인터류킨 6(IL-6) 억제제 시장 - 아랍에미리트
    • 인터류킨 6(IL-6) 억제제 시장 - 이스라엘
    • 인터류킨 6(IL-6) 억제제 시장 - 남아프리카공화국
  • 인터류킨 6(IL-6) 억제제 시장 - 라틴아메리카
    • 라틴아메리카 : 인터류킨-6(IL-6) 억제제 시장, 질환 유형별, 2019-2032
    • 라틴아메리카 : 인터류킨-6(IL-6) 억제제 시장, 유통 채널별, 2019-2032
    • 라틴아메리카 : 인터류킨-6(IL-6) 억제제 시장, 약제 유형별, 2019-2032
    • 인터류킨 6(IL-6) 억제제 시장 - 멕시코
    • 인터류킨 6(IL-6) 억제제 시장 - 브라질
    • 인터류킨 6(IL-6) 억제제 시장 - 아르헨티나

제9장 경쟁 상황

  • 확장과 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • AbbVie
  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson and Johnson Services
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche
  • Teva Pharmaceutical
ksm 23.10.24

The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032, according to a new study by Polaris Market Research. The report "Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing popularity of interleukin-6 (IL-6) inhibitors has led businesses and many organizations to invest in research and development. For example, in December 2022, Tocilizumab (Actemra), administered intravenously (IV), was authorized by the US Food and Drug Administration (FDA) for the management of COVID-19 in hospitalized individuals receiving extra care. Tocilizumab was the first monoclonal antibody approved by the FDA to treat the pandemic virus, thanks to the approval given to Roche. In addition to this, in September 2021, Hetero received approval from the Drug Controller General of India (DCGI) for the sale of a biosimilar version of Tocilizumab, a COVID-19 medication for hospitalized people. Contributions of several organizations and industry participants are significantly augmenting the market's growth worldwide.

The increasing prevalence of autoimmune and inflammatory diseases will likely spur the global market's development. IL-6 is critical in the pathogenesis of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome (CRS). The rising prevalence of these conditions worldwide drives the demand for effective therapies like IL-6 inhibitors.

The increasing prevalence of chronic inflammatory conditions is one of the primary factors likely to enhance the market's growth globally. Chronic inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease are rising globally. For example, as per the estimates, 4 to 16 out of every 10,000 kids in North America and Europe will have juvenile idiopathic arthritis. IL-6 inhibitors have shown efficacy in managing the symptoms and progression of these conditions, driving the demand for IL-6 inhibitors. Henceforth, this heightens the development in the global market.

Interleukin-6 (IL-6) Inhibitors Market Report Highlights

Tocilizumab drug is anticipated to record the largest market share in the year of 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market

Rheumatoid arthritis disease type is expected to garner the largest revenue in the global market due to relatively high prevalence of the diseases

Specialty retailers segment is accounting largest market share of the global revenue in the fiscal year of 2022 as these are a key distribution channel for IL-6 inhibitors

North America held the largest share as of 2022 due to increasing clinical trials among companies and organizations and surging research and development in the industry

The global players include: AbbVie, inc., AstraZeneca, Bausch Health, Johnson and Johnson Services, Novartis, GlaxoSmithKline, Eli Lilly, Teva Pharmaceutical, Regeneron Pharmaceuticals, Roche, and others

Polaris Market Research has segmented the Interleukin-6 (IL-6) Inhibitors market report based on drug type, disease type, and distribution channel, and region:

Interleukin-6 (IL-6) Inhibitors, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Tocilizumab
  • Siltuximab
  • Sylvant

Interleukin-6 (IL-6) Inhibitors, Disease Type Outlook (Revenue - USD Billion, 2019-2032)

  • Rheumatoid Arthritis
  • Castleman's disease
  • Cancers (Renal cancer, Prostate cancer)
  • Arteritis

Interleukin-6 (IL-6) Inhibitors, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

  • Retail Pharmacies
  • Hospital pharmacies
  • Specialty pharmacies
  • Online pharmacies
  • Other Sales Channel

Interleukin-6 (IL-6) Inhibitors, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Interleukin-6 (IL-6) Inhibitors Market Insights

  • 4.1. Interleukin-6 (IL-6) Inhibitors Market - Distribution Channel Snapshot
  • 4.2. Interleukin-6 (IL-6) Inhibitors Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of rheumatoid arthritis (RA)
      • 4.2.1.2. High popularity of interleukin-6 inhibitor
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High development cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Interleukin-6 (IL-6) Inhibitors Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Rheumatoid Arthritis
    • 5.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Rheumatoid Arthritis, by Region, 2019-2032 (USD Billion)
  • 5.4. Castleman's disease
    • 5.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Castleman's disease, by Region, 2019-2032 (USD Billion)
  • 5.5. Cancers (Renal cancer, Prostate cancer)
    • 5.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Cancers (Renal cancer, Prostate cancer), by Region, 2019-2032 (USD Billion)
  • 5.6. Arteritis
    • 5.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Arteritis, by Region, 2019-2032 (USD Billion)

6. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Tocilizumab
    • 6.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Tocilizumab, by Region, 2019-2032 (USD Billion)
  • 6.4. Siltuximab
    • 6.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Siltuximab, by Region, 2019-2032 (USD Billion)
  • 6.5. Sylvant
    • 6.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Sylvant, by Region, 2019-2032 (USD Billion)

7. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Retail Pharmacies
    • 7.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospital pharmacies
    • 7.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Hospital pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Specialty pharmacies
    • 7.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Specialty pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Online pharmacies
    • 7.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Online pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.7. Other sales channel
    • 7.7.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Other sales channel, By Region, 2019-2032 (USD Billion)

8. Global Interleukin-6 (IL-6) Inhibitors Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Interleukin-6 (IL-6) Inhibitors Market - North America
    • 8.3.1. North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Interleukin-6 (IL-6) Inhibitors Market - U.S.
      • 8.3.4.1. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Interleukin-6 (IL-6) Inhibitors Market - Canada
      • 8.3.5.1. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Interleukin-6 (IL-6) Inhibitors Market - Europe
    • 8.4.1. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Interleukin-6 (IL-6) Inhibitors Market - UK
      • 8.4.4.1. UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Interleukin-6 (IL-6) Inhibitors Market - France
      • 8.4.5.1. France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Interleukin-6 (IL-6) Inhibitors Market - Germany
      • 8.4.6.1. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Interleukin-6 (IL-6) Inhibitors Market - Italy
      • 8.4.7.1. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Interleukin-6 (IL-6) Inhibitors Market - Spain
      • 8.4.8.1. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Interleukin-6 (IL-6) Inhibitors Market - Netherlands
      • 8.4.9.1. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Interleukin-6 (IL-6) Inhibitors Market - Russia
      • 8.4.10.1. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Interleukin-6 (IL-6) Inhibitors Market - Asia Pacific
    • 8.5.1. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Interleukin-6 (IL-6) Inhibitors Market - China
      • 8.5.4.1. China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Interleukin-6 (IL-6) Inhibitors Market - India
      • 8.5.5.1. India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Interleukin-6 (IL-6) Inhibitors Market - Malaysia
      • 8.5.6.1. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Interleukin-6 (IL-6) Inhibitors Market - Japan
      • 8.5.7.1. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Interleukin-6 (IL-6) Inhibitors Market - Indonesia
      • 8.5.8.1. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Interleukin-6 (IL-6) Inhibitors Market - South Korea
      • 8.5.9.1. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Interleukin-6 (IL-6) Inhibitors Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Interleukin-6 (IL-6) Inhibitors Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Interleukin-6 (IL-6) Inhibitors Market - UAE
      • 8.6.5.1. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Interleukin-6 (IL-6) Inhibitors Market - Israel
      • 8.6.6.1. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Interleukin-6 (IL-6) Inhibitors Market - South Africa
      • 8.6.7.1. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Interleukin-6 (IL-6) Inhibitors Market - Latin America
    • 8.7.1. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Interleukin-6 (IL-6) Inhibitors Market - Mexico
      • 8.7.4.1. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Interleukin-6 (IL-6) Inhibitors Market - Brazil
      • 8.7.5.1. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Interleukin-6 (IL-6) Inhibitors Market - Argentina
      • 8.7.6.1. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bausch Health
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. GlaxoSmithKline
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson and Johnson Services
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Regeneron Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teva Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제